Document is current
Any future updates will be listed below
-
Authors
Pelouto, Farah
Papri, Nowshin
Haagsma, Juanita A.
Cornblath, David R.
Nobile-Orazio, Eduardo
Wiegers, Eveline J. A.
Harbo, Thomas
Rajabally, Yusuf A.
van Doorn, Pieter A.
Gorson, Kenneth C.
Terwee, Caroline B.
Jacobs, Bart C.
Horton, Mike C.
,
Antonini, G.
Arends, S.
Attarian, S.
Barroso, F. A.
Bateman, K.
Benedetti, L.
van den Berg, B.
van den Bergh, P. Y. K.
Binda, D.
Bürmann, J.
Casasnovas, C.
Cavaletti, G.
Cejas, L. L.
Cornblath, D. R.
Dardiotis, E.
Davidson, A.
Doets, A. Y.
van Doorn, P. A.
Eftimov, F.
Feasby, T. E.
Galassi, G.
Goldstein, J. M.
Gorson, K. C.
Granit, V.
Gutiérrez-Gutiérrez, G.
Harbo, T.
Holt, J. K. L.
Hsieh, S. T.
Islam, B.
Islam, Z.
Jacobs, B. C.
Katzberg, H. D.
de Koning, L. C.
van der Kooi, A. J.
Kramers, J. C. H. M.
Kuitwaard, K.
Kuwabara, S.
Lehmann, H. C.
Leonhard, S. E.
Lucy, S. T.
Luijten, L. W. G.
Marfia, G. A.
Martínez- Martínez, M. M.
Martín-Aguilar, L.
Mataluni, G.
Miller, J. A. L.
Mohammad, Q. D.
de la Prida, M. Morales
Nobile-Orazio, E.
Nowak, R. J.
Pardo, J.
Pelouto, F.
Péréon, Y.
Querol, L.
Rajpar, A.
Rajabally, Y. A.
Rinaldi, S.
Ripellino, P.
Roodbol, J.
Samijn, J. P. A.
Schenone, A.
Tous, M. J. Sedano
Shahrizaila, N.
Sheikh, K. A.
Sindrup, S. H.
Thomma, R. C. M.
Tigner, D.
Verboon, J. C.
Vermeij, F. H.
Vytopil, M. V.
Waheed, W.
Walgaard, C.
Wang, Y. Z.
Wiegers, E. J. A.
Wirtz, P. W.
Wilkerson, C.
van Woerkom, M.
-
Funding
Funding for this research was provided by:
Prinses Beatrix Spierfonds (W. OR20-04)
- License Information
-
More Information
Article History
Received: 19 October 2025
Revised: 4 February 2026
Accepted: 5 February 2026
First Online: 25 February 2026
Declarations
:
: F. Pelouto, N. Papri, J.A. Haagsma, D. R. Cornblath, E. J. A. Wiegers, K. C. Gorson, and M. C. Horton have no competing interests to declare that are relevant to the content of this article. C.B. Terwee is one of the founders of COSMIN. P.A. van Doorn received research grants from Prinses Beatrix Spierfonds, The Netherlands Organisation for Health Research and Development (ZonMW), Sanquin Blood Supply, Takeda, and Grifols; he is a member of Scientific Advisory Committee/Steering Committee Trials for Annexon, Argenx, Hansa, Octapharma, Sanofi, and Roche. All grants and fees were paid to his institution. B.C. Jacobs received research grants for work outside the current study from Baxalta, Grifols, CSL-Behring, Annexon, Hansa Biopharma, Roche, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International, and Horizon 2020 and consultancy fees from Roche for activities outside the current study. All grants and fees were paid to his institution. He is the chair of the Steering Committee of the International GBS Outcome Study (IGOS). Y. A. Rajabally has received consultancy honoraria from Sanofi, Argenx, Janssen, LFB, Polyneuron, Grifols, Takeda, Dianthus, Vitaccess, has received educational sponsorships from LFB and CSL Behring and has obtained research grants from LFB. T. Harbo is a member of Scientific Advisory Committee/Steering Committee for Annexon and member of Scientific Advisory Board of the GBS-CIDP Foundation International. He received honoraria for a teaching course from Takeda. E. N. Orazio reports personal fees for Advisory or Scientific Board from ArgenX (Belgium), Dianthus (USA); Janssen (USA), LFB (France), Longboard Pharma (USA), Sanofi (USA), Janssen (USA) and Takeda (Italy). He received personal fees for lecturing from CSL-Behring (Italy). He received a research grant from Baxalta/Takeda, USA, on Multifocal Motor Neuropathy, and from Agenzia Italiana del Farmaco (AIFA) and GBS/CIDP Foundation International for a randomised trial with rituximab in CIDP. He received travel grants to attend scientific meetings from Kedrion (Italy).
: The questionnaire and procedure performed in this study were in accordance with the principles of the Declaration of Helsinki (59th WMA General Assembly, Seoul, October 2008) and the Medical Research Involving Human Subjects (WMO). The IGOS was approved by the Medical Ethics Review Committee of the Erasmus MC Medical University Rotterdam in 2012. All participating centres obtained approval from their local Institutional Review Boards (IRBs). Written informed consent was obtained from all participants or their legal representatives prior to inclusion. IGOS is registered at ClinicalTrials.gov (identifier: NCT01582763).
